Results 41 to 50 of about 2,223,665 (257)

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors [PDF]

Experimental & Molecular Medicine, 2018
Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic properties, constitutes the only effective first-line drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Despite its capacity to increase survival in HCC patients, its success is quite low in the long term owing to the development of ...
Carolina Méndez-Blanco, Flavia Fondevila, Andrés García-Palomo, Javier González-Gallego, José L. Mauriz   +4 more
openaire   +4 more sources

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1

Signal Transduction and Targeted Therapy, 2020
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we
Junjie Xu, Lin Ji, Yuelong Liang, Zhe Wan, Wei Zheng, Xiaomin Song, Kirill Gorshkov, Qiming Sun, Hui Lin, Xueyong Zheng, Jiang Chen, Ren-an Jin, Xiao Liang, Xiujun Cai   +13 more
doaj   +1 more source

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

Signal Transduction and Targeted Therapy, 2021
The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months.
Junjie Xu, Lin Ji, Yeling Ruan, Zhe Wan, Zhongjie Lin, Shunjie Xia, Liye Tao, Junhao Zheng, Liuxin Cai, Yifan Wang, Xiao Liang, Xiujun Cai   +11 more
doaj   +1 more source

About sorafenib in castration-resistant prostate cancer

Annals of Oncology, 2008
n ...
Colloca, G., Checcaglini, F., Venturino, A.   +2 more
openaire   +3 more sources

Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Response [PDF]

Molecular Cancer Therapeutics, 2014
We are aware that sorafenib binds to plasma proteins. At steady state, when sorafenib is orally administered at 800 mg/d, accumulation ratios are 5.7 to 6.4, indicating that it has a good distribution range.
openaire   +3 more sources

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells [PDF]

International Journal of Molecular Sciences, 2021
Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade. However, resistance to sorafenib limits patient response and presents a major hurdle during HCC treatment.
Tingting Shi, Hisakazu Iwama, Koji Fujita, Hideki Kobara, Noriko Nishiyama, Shintaro Fujihara, Yasuhiro Goda, Hirohito Yoneyama, Asahiro Morishita, Joji Tani, Mari Yamada, Mai Nakahara, Kei Takuma, Tsutomu Masaki   +13 more
openaire   +2 more sources

Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib

Biological and Pharmaceutical Bulletin, 2011
Sorafenib and sunitinib is a small molecule inhibitor of certain receptor tyrosine kinases, and have improved outcomes for patients with advanced renal cell carcinoma. Inhibitory concentration of 50% cell growth of sorafenib significantly rose to 6.4-fold in a multidrug resistance protein 2 (MRP2) transfected cell line versus control cell line.
Shibayama, Yoshihiko, Nakano, Kou, Maeda, Hiroshi, Taguchi, Miyuki, Ikeda, Ryuji, Sugawara, Mitsuru, Iseki, Ken, Takeda, Yasuo, Yamada, Katsushi   +8 more
openaire   +3 more sources